title: [Cost analysis and degree of hypercholesterolemia control in type 2 diabetic patients according to different groups and scientific societies].
abstract: OBJECTIVE
  To analyse the cost and describe the degree of control of the hypercholesterolaemia of type-2 diabetic (DM2) patients according to different groups and scientific societies.
  
  
  METHODS
  Retrospective cross-sectional study.
  
  
  METHODS
  Rural health area.
  
  
  METHODS
  All DM2 patients monitored in the health area (n = 338).
  
  
  RESULTS
  Gathering of data on clinical histories, determination of cardiovascular risk, LDL-C concentration and total/HDL cholesterol index. DM2 prevalence was 3.08%; annual incidence, 2.55/1000; 45.2% presented hypercholesterolaemia; 16.9% received lipid-lowering treatment; and 20.1% (n = 68) had DM2 with cardiovascular disease. According to the criteria of the GEDAPS-99, European Consensus-98 (Framingham table), Sheffield Group (objectives of the European Consensus-98) and PAPPS-99 for primary prevention, 59.3%, 58.4%, 24.5% and 17.7%, respectively, of hypercholesterolaemic patients were poorly controlled. The percentages of hypercholesterolaemic patients who in each case should receive treatment were: 64.9%, 66.1%, 36.4% and 29.6%. Expenditure in thousands of pesetas every 28 days to achieve proper control of these patients was 282, 423, 274 and 117. The criteria on secondary prevention of the GEDAPS-99 and European Consensus-98 gave figures of 81% and 72.4%, respectively, of poor control of Hypercholesterolaemia. 82.7% and 77.5% of these patients should receive treatment. Expenditure in thousands of pesetas every 28 days to achieve proper control of these patients was 342 and 210.
  
  
  CONCLUSIONS
  The degree of control and the costs of hypercholesterolaemia in both primary and secondary prevention vary enormously, depending on the criterion used by the group or scientific society.
authors.affiliation: ABS Sta, Eugènia de Berga, Unidad Docente de MFyC Centro, Barcelona.
authors.forename: S
authors.initials: S
authors.lastname: Narejos
authors.forename: J
authors.initials: J
authors.lastname: Espinàs
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez
authors.forename: R M
authors.initials: RM
authors.lastname: Salla
authors.forename: C
authors.initials: C
authors.lastname: Blay
authors.forename: A
authors.initials: A
authors.lastname: Puente
authors.forename: M
authors.initials: M
authors.lastname: Cantero
authors.forename: J
authors.initials: J
authors.lastname: Alsina
authors.forename: M C
authors.initials: MC
authors.lastname: López
mesh_terms: D000368:Aged; D003365:Costs and Cost Analysis; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000191:economics* / Q000209:etiology / Q000628:therapy*; D008297:Male; D012189:Retrospective Studies; D012958:Societies, Scientific